Return On Equity
-411%
Third-party reference; reporting period not verified
Period Q3 2026 · Filed 13 Nov 2026
Return On Equity
-411%
Third-party reference; reporting period not verified
Return On Assets
-225%
Third-party reference; reporting period not verified
Operating Margin
0%
Third-party reference; reporting period not verified
Current Ratio
45.95x
Third-party reference; reporting period not verified
Quick Ratio
28.17x
Third-party reference; reporting period not verified
Debt-to-equity
0.06x
Third-party reference; reporting period not verified
NetIncomeLoss YoY
-850%
Trailing 12 months · Through 30 Sep 2026
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
-411%
Third-party reference; reporting period not verified
|
|
| Return On Assets |
-225%
Third-party reference; reporting period not verified
|
|
| Operating Margin |
0%
Third-party reference; reporting period not verified
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
45.95x
Third-party reference; reporting period not verified
|
|
| Quick Ratio |
28.17x
Third-party reference; reporting period not verified
|
|
| Debt-to-equity |
0.06x
Third-party reference; reporting period not verified
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
-850%
Trailing 12 months · 30 Sep 2026
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
1,568,216
Period-end balance · 13 Nov 2026
|
-94% |
| Common Stock, Shares, Outstanding |
1,568,241
Period-end balance · 30 Sep 2026
|
-94% |
| Common Stock, Value, Issued |
$157
Period-end balance · 30 Sep 2026
|
-94% |
| Weighted Average Number of Shares Outstanding, Basic |
1,516,284
Reported period · 30 Sep 2026
|
+18% |
| Weighted Average Number of Shares Outstanding, Diluted |
1,516,284
Reported period · 30 Sep 2026
|
+18% |
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accrued Liabilities, Current |
$9,741
Period-end balance · 30 Sep 2026
|
-5.6% |
| Assets |
$3,097,012
Period-end balance · 30 Sep 2026
|
-79% |
| Assets, Current |
$2,556,390
Period-end balance · 30 Sep 2026
|
-82% |
| Cash and Cash Equivalents, at Carrying Value |
$1,579,689
Period-end balance · 30 Sep 2026
|
-73% |
| Common Stock, Par or Stated Value Per Share |
0.0001
Period-end balance · 30 Sep 2026
|
0% |
| Common Stock, Shares Authorized |
475,000,000
Period-end balance · 30 Sep 2026
|
0% |
| Common Stock, Shares, Issued |
1,568,241
Period-end balance · 30 Sep 2026
|
-94% |
| Deferred Tax Assets, Gross |
$2,963,342
Period-end balance · 30 Sep 2026
|
+1125% |
| Deferred Tax Assets, Operating Loss Carryforwards |
$2,961,286
Period-end balance · 30 Sep 2026
|
+1124% |
| Deferred Tax Assets, Valuation Allowance |
$2,963,342
Period-end balance · 30 Sep 2026
|
+1125% |
| Earnings Per Share, Basic |
-1.5
Trailing 12 months · 30 Sep 2026
|
-148% |
| Earnings Per Share, Diluted |
-1.5
Trailing 12 months · 30 Sep 2026
|
-148% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent |
0.21
Reported period · 30 Sep 2026
|
0% |
| General and Administrative Expense |
$3,320,401
Trailing 12 months · 30 Sep 2026
|
+220% |
| Lessee, Operating Lease, Liability, to be Paid |
$599,389
Period-end balance · 30 Sep 2026
|
+828% |
| Lessee, Operating Lease, Liability, to be Paid, Year Four |
$69,982
Period-end balance · 30 Sep 2026
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$154,008
Period-end balance · 30 Sep 2026
|
+228% |
| Lessee, Operating Lease, Liability, to be Paid, Year Three |
$129,022
Period-end balance · 30 Sep 2026
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$154,330
Period-end balance · 30 Sep 2026
|
|
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$57,299
Period-end balance · 30 Sep 2026
|
+1578% |
| Liabilities |
$551,831
Period-end balance · 30 Sep 2026
|
+197% |
| Liabilities and Equity |
$3,097,012
Period-end balance · 30 Sep 2026
|
-79% |
| Liabilities, Current |
$143,300
Period-end balance · 30 Sep 2026
|
-23% |
| Operating Income (Loss) |
-$12,431,266
Trailing 12 months · 30 Sep 2026
|
-197% |
| Operating Lease, Liability |
$542,090
Period-end balance · 30 Sep 2026
|
+786% |
| Operating Lease, Liability, Current |
$133,559
Period-end balance · 30 Sep 2026
|
+118% |
| Operating Lease, Liability, Noncurrent |
$408,531
Period-end balance · 30 Sep 2026
|
|
| Operating Lease, Right-of-Use Asset |
$540,622
Period-end balance · 30 Sep 2026
|
+795% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.0487
Period-end balance · 30 Sep 2026
|
-56% |
| Preferred Stock, Par or Stated Value Per Share |
0.0001
Period-end balance · 30 Sep 2026
|
0% |
| Preferred Stock, Shares Authorized |
25,000,000
Period-end balance · 30 Sep 2026
|
0% |
| Preferred Stock, Shares Issued |
1,000,000
Period-end balance · 30 Sep 2026
|
0% |
| Preferred Stock, Shares Outstanding |
1,000,000
Period-end balance · 30 Sep 2026
|
0% |
| Research and Development Expense |
$1,952,587
Reported period · 30 Sep 2026
|
+188% |
| Retained Earnings (Accumulated Deficit) |
-$14,104,350
Period-end balance · 30 Sep 2026
|
-695% |
| Share-based Payment Arrangement, Expense |
$154,009
Reported period · 30 Sep 2026
|
|
| Stockholders' Equity Attributable to Parent |
$2,545,181
Period-end balance · 30 Sep 2026
|
-82% |
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest financial period: Q3 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
13 Nov 2026
Page type
Company facts
Latest period
Q3 2026
SEC-backed company facts were refreshed from filings filed on 13 Nov 2026.
Benchmark Context
Return On Equity does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with Curanex Pharmaceuticals Inc's recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-11-13) highlights Return On Equity -411.1%, Return On Assets -225.1%, and Operating Margin 0.0%.
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
Use these links to compare CURX - Curanex Pharmaceuticals Inc against other SEC filers on the same metric, then verify the company history from the paired facts page.
Latest value: -850%
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
15.6/100
Weak Confidence medium
-411%
Metric score 0.0/100
-225%
Metric score 0.0/100
Debt-to-equity
Return On Equity, Return On Assets, and Operating Margin
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
CIK / security context first